NCT04374708 is a clinical trial of fMRI in Gender Dysphoria, sponsored by University of California, Los Angeles.

Who is sponsoring NCT04374708?

NCT04374708 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT04374708?

Interventions in NCT04374708: fMRI.

What condition does NCT04374708 study?

NCT04374708 studies Gender Dysphoria.

Is NCT04374708 still recruiting?

NCT04374708 is currently terminated. Last updated 22 March 2023.

Last reviewed 2023-03-22 · How we verify

NCT04374708

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gender Identity and Own Body Perception

Terminated Last updated 22 March 2023

What this trial tests

trial testing fMRI in Gender Dysphoria in 132 participants. Terminated before completion.

Timeline

22 February 2018

Primary endpoint
1 February 2021

31 December 2021

Quick facts

Lead sponsor	University of California, Los Angeles
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	132
Start date	22 February 2018
Primary completion	1 February 2021
Estimated completion	31 December 2021
Sites	1 location across United States

Drugs / interventions tested

fMRI — full drug profile →

Conditions studied

Gender Dysphoria — all drugs for Gender Dysphoria →

Sponsor

University of California, Los Angeles

Who can join

Adults 18 to 40, any sex, with Gender Dysphoria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will provide valuable information on the neurobiological underpinning of gender dysphoria (GD) and the effects of sex hormones, and promises to uncover functional or structural neural patterns that could predict outcome in terms of body image and quality of life after cross-sex hormone treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of fMRI

Trials testing the same drug.

NCT06593470 — Mindfulness-Based Substance Use Prevention (MINDS-UP) · NA · not yet recruiting
NCT07259902 — FMRI Study on DC/TMD Patients · NA · not yet recruiting
NCT05524493 — High-field MR Imaging in Migraine, Visual Snow and Epilepsy · recruiting
NCT06673303 — Investigating The Role of Noise Correlations in Learning · NA · recruiting
NCT06467292 — Speech Motor Learning and Retention (Master Protocol) · NA · recruiting

Other recruiting trials for Gender Dysphoria

Currently open trials in the same condition.

NCT06969326 — Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy · Phase 3 · recruiting
NCT07147166 — Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affir · NA · recruiting
NCT06639776 — Sexual Functioning After Erection Prosthesis Placement in Post Phalloplasty Transgender Persons · recruiting
NCT06639763 — Erectile Aid Use in Post-phalloplasty and Post-metoidioplasty Transgender Patients · recruiting
NCT06351501 — Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering from Gender Dysphoria · Phase 3 · recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04374708 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 22 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04374708.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing